2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1229

AR882, a Potent and Selective Uric Acid Lowering Agent Acting Through Inhibition of Uric Acid Reuptake, Shows Excellent Pharmacokinetics and Pharmacodynamics in a Phase 1 Clinical Trial
Abstract Number: 1230

Do Serum Urate-Associated Genetic Variants Influence Gout Risk in People on Diuretics? Analysis of the UK Biobank
Abstract Number: 1231

Improvement in Hepatic Fibrosis Estimated by Fibrosis-4 (FIB-4) Index in Subjects with Chronic Refractory Gout Treated with Pegloticase
Abstract Number: 1232

Whole Blood RNA Sequencing Study of Gout Cases and Controls Demonstrates Transcriptomic Differences with Relevance to Inflammatory Cell Activation
Abstract Number: 1233

Identification and Characterization of a Novel Dysfunction Variant p.I242T in ABCG2 Transporter in a Family with Early-onset Hyperuricamia and Gout
Abstract Number: 1234

Inconsistency in Uric Acid Reference Ranges Among 20 Top United States Hospitals: What Is “Normal”?
Abstract Number: 1235

Monthly Dosing of ImmTOR Tolerogenic Nanoparticles Combined with Pegylated Uricase (Pegadricase) Mitigates Formation of Anti-Drug Antibodies Resulting in Sustained Uricase Activity in Symptomatic Gout Patients
Abstract Number: 1236

Subcutaneous or Oral Methotrexate Exposure and Response to Pegloticase in Uncontrolled Gout Patients in a Community Rheumatology Practice
Abstract Number: 1237

Treatment with OLT1177™, an Oral NLRP3 Inflammasome Inhibitor, Reduces Systemic Inflammation During Gout Flares in Humans
Abstract Number: 1238

Monosodium Urate and Calcium Pyrophosphatecrystal-induced Interleukin 1 Production Depends on Glucose Uptake Through Glut1 Transporter
Abstract Number: 1239

The Association Between Urate and CSF Markers of Alzheimer’s Disease in a Population-Based Sample of 70-Year-Olds
Abstract Number: 1240

A Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Anakinra in Difficult-To-Treat Acute Gouty Arthritis: The anaGO Study
Abstract Number: 1241

Further Characterizing Morphea Subsets Using a Multi-center, Prospective, Cross-sectional Analysis of Morphea in Adults and Children
Abstract Number: 1242

Impact of Smoking Status on Remission in Hidradenitis Suppurativa
Abstract Number: 1243

Anakinra Treatment in Recurrent Pericarditis: Single Center Experience

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].